Cellectar Biosciences, Inc. Email Format

Biotechnology ResearchNew Jersey, United States11-50 Employees

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on discovering and developing cancer therapies, both independently and through research collaborations. It aims to advance a proprietary phospholipid drug conjugate delivery platform to create cancer cell-targeting treatments that seek to improve efficacy while reducing off-target effects. The company’s lead asset is iopofosine I-131, a small-molecule drug conjugate designed to deliver radioactive iodine-131 directly to cancer cells, with additional preclinical programs and multiple partnered drug conjugate assets in its pipeline. The organization pursues both internal programs and collaborations with partners to advance oncology therapies.

Based in Florham Park, New Jersey, the company operates as a small to mid-sized biotechnology research firm focused on cancer treatment. In 2026, it announced that efficacy results from a subset of patients in its Phase 2 CLOVER WaM trial for relapsed or refractory Waldenström macroglobulinemia would be presented at the American Society of Clinical Oncology meeting.

Sign up for free to view info

Company overview Employee directory